Reuters logo
BRIEF-SYROS PHARMACEUTICALS PRESENTS BIOMARKER DATA FROM ONGOING PHASE 2 TRIAL OF SY-1425
October 5, 2017 / 12:25 PM / in 12 days

BRIEF-SYROS PHARMACEUTICALS PRESENTS BIOMARKER DATA FROM ONGOING PHASE 2 TRIAL OF SY-1425

Oct 5 (Reuters) - Syros Pharmaceuticals Inc:

* SYROS PHARMACEUTICALS INC - PRESENTS BIOMARKER DATA FROM ITS ONGOING PHASE 2 CLINICAL TRIAL OF SY-1425 IN GENOMICALLY DEFINED AML AND MDS PATIENTS

* SYROS PHARMACEUTICALS INC - DATA FROM TRIAL SUPPORT POTENTIAL CLINICAL UTILITY OF BIOMARKER TEST FOR PATIENT SELECTION

* SYROS PHARMACEUTICALS INC - EXPECTS TO PRESENT INITIAL PHASE 2 CLINICAL DATA FOR SY-1425 AT ASH ANNUAL MEETING Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below